Details for New Drug Application (NDA): 214051
✉ Email this page to a colleague
The generic ingredient in IVABRADINE HYDROCHLORIDE is ivabradine hydrochloride. There are nine drug master file entries for this compound. Six suppliers are listed for this compound. Additional details are available on the ivabradine hydrochloride profile page.
Summary for 214051
Tradename: | IVABRADINE HYDROCHLORIDE |
Applicant: | Ingenus Pharms Llc |
Ingredient: | ivabradine hydrochloride |
Patents: | 0 |
Pharmacology for NDA: 214051
Mechanism of Action | Hyperpolarization-activated Cyclic Nucleotide-gated Channel Antagonists |
Suppliers and Packaging for NDA: 214051
Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
---|---|---|---|---|---|---|---|---|
IVABRADINE HYDROCHLORIDE | ivabradine hydrochloride | TABLET;ORAL | 214051 | ANDA | Ingenus Pharmaceuticals, LLC | 50742-362 | 50742-362-60 | 60 TABLET, FILM COATED in 1 BOTTLE (50742-362-60) |
IVABRADINE HYDROCHLORIDE | ivabradine hydrochloride | TABLET;ORAL | 214051 | ANDA | Ingenus Pharmaceuticals, LLC | 50742-363 | 50742-363-60 | 60 TABLET, FILM COATED in 1 BOTTLE (50742-363-60) |
Profile for product number 001
Active Rx/OTC/Discontinued: | RX | Dosage: | TABLET;ORAL | Strength | EQ 5MG BASE | ||||
Approval Date: | Dec 30, 2021 | TE: | AB | RLD: | No | ||||
Regulatory Exclusivity Expiration: | Jan 11, 2025 | ||||||||
Regulatory Exclusivity Use: | PATENT CHALLENGE |
Profile for product number 002
Active Rx/OTC/Discontinued: | RX | Dosage: | TABLET;ORAL | Strength | EQ 7.5MG BASE | ||||
Approval Date: | Dec 30, 2021 | TE: | AB | RLD: | No | ||||
Regulatory Exclusivity Expiration: | Jan 11, 2025 | ||||||||
Regulatory Exclusivity Use: | PATENT CHALLENGE |
Complete Access Available with Subscription